Browsing by Author Chiarion-Sileni, Vanna

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 13 of 13
Issue DateTitleAuthor(s)Citation
2017Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanomaKefford, Richard (Rick); Long, Georgina; Atkinson, Victoria; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Hauschild, Axel; Haydon, Andrew; Larkin, J; Mandalà, Mario; Nyakas, Marta; Santinami, Mario; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicineAdjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma, New England Journal of Medicine, vol.377, 19, 2017,pp 1813-1823
2017Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanomaLong, Georgina; Arance, Ana; Chiarion-Sileni, Vanna; Cowey, C. Lance; Dalle, S; Del Vecchio, M; et al, Various; Gogas, Helen; Mandala, Mario; Schenker, Michael; Weber, Jeffrey; Northern Clinical School: MedicineAdjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma, New England Journal of Medicine, vol.377, 19, 2017,pp 1824-1835
2014Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanomaLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreCombined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, The New England Journal of Medicine, vol.371, 20, 2014,pp 1877-1888
2015Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaCarlino, Matteo; Long, Georgina; Chiarion-Sileni, Vanna; Cowey, C. Lance; Dummer, R; et al, Various; Gonzalez, Rene; Grob, Jean-Jacques; Lao, Christopher; Larkin, James; Schadendorf, Dirk; Smylie, Michael; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentreCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, The New England Journal of Medicine, vol.373, 1, 2015,pp 23-34
2015Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialLong, Georgina; Chiarion-Sileni, Vanna; De Braud, Filippo; et al, Various; Garbe, Claus; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Jouary, Thomas; Larkin, James; Levchenko, Evgeny; Stroyakovskiy, Daniil; Central Clinical School: The Sydney Cancer CentreDabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, The Lancet, vol.386, 9992, 2015,pp 444-451
2017Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialLong, Georgina; Arance, Ana; Chiarion-Sileni, Vanna; Davies, Michael; Del Vecchio, M; Flaherty, Keith; Grob, Jean-Jacques; Hogg, David; Huang, Yingjie; Lebbe, Celeste; Lesimple, Thierry; Márquez-Rodas, Ivan; Meyer, Nicolas; Mookerjee, Bijoyesh P; Mortier, Laurent; Moschos, S; Robert, Caroline; Saiag, Philippe; Thomas, Luc; Zhang, Ying; Northern Clinical School: MedicineDabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial, The Lancet Oncology, vol.18, 7, 2017,pp 863-873
2013Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced MelanomaKefford, Richard (Rick); Chiarion-Sileni, Vanna; Eggermon, Alexander; et al, Various; Grob, Jean Jacques; Mackiewicz, Jacek; Mortier, Laurent; O'Day, Steven; Robert, Caroline; Schachter, Jacob; Testori, Alessandro; Western Clinical School: Westmead Millennium InstituteFinal Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma, Journal of Clinical Oncology, vol.31, 9, 2013,pp 1211-1218
2009Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutationMann, Graham; Torres, Paula; Agata, Simona; Callegaro, Monia; Casella, Cinzia; Chiarion-Sileni, Vanna; et al, various; Malacrida, Sandro; Quaggio, Monica; Rossi, Elisabetta; Scaini, Maria Chiara; Vecchiato, Antonella; Zullato, Daniela; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Medicine (Westmead)Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation, MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, vol.671, 1,pp 26-32
2017Health-related quality of life results from the phase III CheckMate 067 studyLong, Georgina; Chiarion-Sileni, Vanna; Cowey, C; et al, Various; Gonzalez, R; Grob, Jean-Jacques; Hodi, F. Stephen; Larkin, James; Rutkowski, Piotr; Schadendorf, Dirk; Wolchok, Jedd D.; Northern Clinical School: MedicineHealth-related quality of life results from the phase III CheckMate 067 study, European Journal of Cancer, vol.82, N/A, 2017,pp 80-91
2015Improved overall survival in melanoma with combined dabrafenib and trametinibLong, Georgina; Chiarion-Sileni, Vanna; Dummer, R; et al, Various; Grange, Florent; Karaszewska, Boguslawa; Lichinitser, Michael; Mackiewicz, Andrzej; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Schachter, Jacob; Stroiakovski, Daniel; Central Clinical School: The Sydney Cancer CentreImproved overall survival in melanoma with combined dabrafenib and trametinib, New England Journal of Medicine, vol.372, 1, 2015,pp 30-39
2017Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialMcNeil, Catriona; Arance, A; Ascierto, Paolo A; Bastholt, Lars; Chiarion-Sileni, Vanna; Del Vecchio, Michele; et al, Various; Hamid, Omid; Lebbe, Celeste; Mackiewicz, Andrzej; Robert, Caroline; Rutkowski, Piotr; Central Clinical School: MedicineIpilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial, The Lancet Oncology, vol.18, 5, 2017,pp 611-622
2017Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaCarlino, Matteo; Long, Georgina; Chiarion-Sileni, Vanna; Cowey, C; et al, Various; Gonzalez, Rene; Grob, Jean-Jacques; Lao, Christopher; Rutkowski, Piotr; Schadendorf, Dirk; Wagstaff, John; Wolchok, Jedd D.; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicineOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.377, 14, 2017,pp 1345-1356
2017Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsLong, Georgina; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Garbe, Claus; Hauschild, Axel; Karaszewska, Boguslawa; Levchenko, Evgeny; Schachter, Jacob; Schadendorf, D; Stroiakovski, Daniel; Northern Clinical School: MedicineThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, European Journal of Cancer, vol.82, N/A, 2017,pp 45-55